Pacific Software Inc Acquires 10763942 Canada, Inc. from PurMinds Holdings Inc., Including its PurMinds™ Products and Research Partners

DANA POINT, Calif., Aug. 26, 2025 /PRNewswire/ - Pacific Software Inc. OTC markets, August 25, 2025, today announced the acquisition of all the outstanding shares from PurMinds Holdings Inc. of its subsidiary 10763942 Canada Inc. ("107 Canada") and its PurMinds™ asset portfolio. "The company is a clinical-stage neuro-medicine development entity focused on advancing a robust pipeline of small molecules and psychoactive compounds for the treatment of neurological and psychiatric disorders under a share purchase agreement" stated. Mr Harrysen Mittler CEO.  "This strategic transaction with Pacific Software Inc. will result in 10763942 Canada Inc.  accelerating its growth trajectory and enhancing shareholder value."

107 Canada is a pioneering neuro-medicine company with a mission to transform the lives of patients with neurological conditions by pursuing next-generation precision neuromedicine solutions addressing global unmet medical needs. PurMinds' business strategy is focused on advancing a robust small molecule pipeline, including proprietary botanical psilocybin formulations and novel neuroplastogens, that aim to restore neuronal functions impaired by neuroinflammation, structural degeneration, and reduced plasticity. 107 Canada is also in an exclusive strategic partnership with a world-leading technology in developing precision neuromedicine and early diagnostic solutions for neurological patients, and is poised to commence global commercialization in the short- and- medium term.

The current management team of 107 Canada is expected to assume leadership roles in the company and elect a new Board of Directors of Pacific Software Inc. which may consider a name change to PurMinds Enterprises, if available.

"This business combination represents a significant milestone for PurMinds and 107 Canada," said Janet Qi, Founder and CEO "Both our small molecule and botanical psilocybin clinical programs have entered a critical point of development. Meanwhile, the GMP-grade production and supply of botanical psilocybin is at the cusp of fulfilling significant collaboration with established partners and gaining market share. As a publicly quoted company, we are now poised to access new capital markets, expand our operations, and deliver greater value to our stakeholders."

About PurMinds^™

PurMinds™ is a neuro-medicine development company pursuing breakthrough solutions to neurological and psychiatric disorders through a precision neuromedicine approach. Its clinical pipeline includes novel, neuroprotective compounds that restore neuronal functions and can address multiple clinical indications with significant unmet patient needs. Established in May 2018 in Ontario, Canada, 107 Canada was granted a Controlled Drugs and Substances License by Health Canada in 2020. Over the past years, the Company has conducted extensive R&D work developing its proprietary botanical psilocybin formulations, has established a portfolio of unique technical asset and intellectual property as well as strong strategic partnerships with world-leading entities. PurMinds™ champions a de-risked business model that includes long-term value creation through drug development focused on therapeutics that induce neuroplasticity and modulate neuro-inflammation, and a short- and mid-term revenue paths by developing and producing precision medicine tools for early detection and risk assessment of neurological conditions. For more information about PurMinds™, please visit the Company's website at PurMinds.com.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to known and unknown risks, uncertainties and assumptions and accordingly, actual results and future events could differ materially from those expressed or implied in such statements. You are hence cautioned not to place undue reliance on forward-looking statements. All statements other than statements of present or historical fact are forward-looking statements, including statements with respect to PurMinds™' future business plans and partnerships. Forward-looking statements include words or expressions such as "proposed", "anticipated", "will", "subject to", "near future", "in the event", "would", "expect", "prepared to" and other similar words or expressions and include, but are not limited to: the ability of PurMinds™ to secure patent protection; the regulatory environment in which PurMinds™ operates; the ability of PurMinds™ to carry out its business plans and unforeseen challenges in carrying out such plans; trends in the future use of psychedelics; general business, economic, competitive, political and social uncertainties; the state of capital markets; and other unforeseen events, developments, or factors causing any of the aforesaid expectations, assumptions, and other factors ultimately being inaccurate or irrelevant. The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We disclaim any obligation to update or revise these forward-looking statements, except as required by applicable law.

SOURCE Pacific Software Inc.